I-Mab Announces Participation at Jefferies and Piper Conferences in November

2023.11.06

ROCKVILLE, Md. and SHANGHAI, China , Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB ) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

2023.11.02

FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study led by I-Mab partner HI-Bio I-Mab has full development and commercialization rights of felzartamab in Greater China for all indications, with Phase 3 multiple myeloma data

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

2023.11.01

ROCKVILLE, MD , U.S. and SHANGHAI, China , Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB ) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel